Ocumension Therapeutics reported unaudited consolidated earnings results for the six months ended June 30, 2021. For the six months, the company announced revenue of RMB 20,803,000 compared to RMB 1,952,000 a year ago. Loss for the period was RMB 69,609,000 compared to RMB 1,741,770,000 a year ago. Basic and diluted loss per share was RMB 0.12 compared to RMB 27 a year ago.